# A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined With SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

> **NCT06829797** · PHASE2 · RECRUITING · sponsor: **Shandong Provincial Hospital** · enrollment: 96 (estimated)

## Conditions studied

- Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Neoadjuvant Therapy(QL1706+SOX Chemotherapy)
- **DRUG:** Neoadjuvant Therapy(SOX Chemotherapy)
- **PROCEDURE:** Radical surgery (D2)
- **DRUG:** Drug: Adjuvant therapy(QL1706+SOX chemotherapy)
- **DRUG:** Drug: Adjuvant therapy(SOX chemotherapy)

## Key facts

- **NCT ID:** NCT06829797
- **Lead sponsor:** Shandong Provincial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-11
- **Primary completion:** 2028-02-29
- **Final completion:** 2028-02-29
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06829797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06829797, "A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined With SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06829797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*